We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Targeting Proteins for Degradation: Characterizing PROTAC Kinetics and Mode of Action Using Live-Cell Assays

Kristin Riching received her Ph.D. from the University of Wisconsin–Madison, where she studied the structural and mechanical properties of collagen fibers and their effects on breast cancer cell migration in invasive ductal carcinoma. She then worked as a postdoctoral researcher at Promega studying ligand-induced protein interactions within the ErbB signaling network and their roles in cancer progression. She has been at Promega for four years and is currently a Senior Scientist developing approaches to monitor functional mechanisms of proteasome-mediated protein degradation.
  • Kristin M. Riching

  • Sr Research Scientist
    Promega Corporation

  • Original Webinar Date: Tuesday, November 13, 2018

Despite the promising potential of PROTAC compounds in new drug discovery strategies, interrogating the multiple steps required to achieve effective PROTAC-mediated target protein degradation remains a challenge. This webinar will describe a platform of live-cell assays that can be used to measure real-time degradation kinetics and key cellular protein interactions mediating the degradation process. Join us to learn how these tools can be used to improve functional and cellular characterization of your PROTAC compounds.

Additional Webinar Information:

A new  generation of heterobifunctional small molecules, termed PROTACs, offer significant potential for new drug discovery strategies by targeting specific proteins for removal from the cell. Characterizing and optimizing PROTACs for degradation efficacy represents a significant challenge, particularly in understanding the individual processes and potential failure points that control the resulting degradation. 

In this webinar, Dr. Riching presents luminescence-based and energy transfer technologies for live-cell, kinetic characterization of PROTAC compound mechanism of action. To quantify key degradation parameters, including rate, recovery, degradation max (Dmax) and DC50, she will show how CRISPR-Cas9 genetic tagging of target proteins with HiBiT enables extended kinetic monitoring of endogenous target protein levels after PROTAC treatment. Using BET family proteins and PROTACs as a case study, she will demonstrate how to measure key cellular mechanisms that affect PROTAC functionality, including permeability, PROTAC compound binding affinity to both target and E3 ligase in lytic and live-cell formats, kinetics of E3 ternary complex formation, target ubiquitination and recruitment to the proteasome.